Business
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\nNEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology-2018 (IDDST-2018), a conference focused on updating the breaking research of drug discovery and development for academic and industrial professionals, taking place in Cambridge, Mass. from August 16-19, 2018.\n AXIM’s Chief Technology Officer, Lekhram Changoer, will bring his expertise to this year’s event as a presenter on the topic of “Novel cGMP Technologies for Extraction, Purification, and Conversion of Cannabinoids for the Pharmaceutical Industry.” His presentation is scheduled to take place on Friday, August 17 from 3:30-3:50 p.m. ET in the Discovery Room, 3rd Floor as part of the Other Enabled Technologies for Drug Discovery session. “It is an honor to be a part of this well-respected community of thought leaders and experts who share the same goal of improving drug discovery and development practices,” said Lekhram Changoer, Chief Technology Officer of AXIM® Biotech. “As a leader in cannabinoid pharmaceutical research, we strive to make sure that we are always sharing our unique knowledge with other professionals in the industry.” Also attending the event will be AXIM’s Chief Executive Officer Dr. George E. Anastassov. He will be available to discuss with other attendees the value of cannabinoids and hemp derivatives, including how AXIM Biotech is using cannabinoids (both synthetic and natural) in its extensive line of pharmaceutical and nutraceutical products. “We are excited to attend IDDST-2018 and share our successful research findings on the science of cannabinoids with other industry peers,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “We are always in search of opportunities to offer insightful contributions to the pharmaceutical community and are looking forward to sharing our knowledge and experience at this internationally recognized industry event.” IDDST-2018 will host 300 participants from 35 countries made up of leading scientists from the academia and indust...